ArticleAsia Pacific allergy2018
Cow's milk oral immunotherapy in real life: 8-year long-term follow-up study.
Article in Asia Pacific allergy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Immune Profile After Oral Immunotherapy in Children With Persistent Cow's Milk Protein Allergy.Allergy, asthma & immunology research · 2026Article
- Insights from long-term follow-up of patients treated with oral immunotherapy for cow's milk allergy.Einstein (Sao Paulo, Brazil) · 2026Article
- Low-dose oral immunotherapy in immunoglobulin E-mediated food allergies.Frontiers in immunology · 2024Review
- Review
- Long-term changes in milk component immunoglobulins reflect milk oral immunotherapy outcomes in Finnish children.Allergy · 2023Article
- Risk factors for discontinuing oral immunotherapy in children with persistent cow milk allergy.Immunity, inflammation and disease · 2022Article
- Cow's Milk Protein Allergy as a Model of Food Allergies.Nutrients · 2021Review
- Oral Immunotherapy (OIT): A Personalized Medicine.Medicina (Kaunas, Lithuania) · 2019Review
- In this July.Asia Pacific allergy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral immunotherapy (OIT) has been recognized as a promising treatment for severe and long-lasting cow's milk (CM) allergy. Once maintenance has been achieved, patients should maintain daily intake of CM to ensure desensitization. Clinical experience concerning long-term follow-up is scarce.
objectiveThe authors aimed to assess long-term efficacy and safety of a maintenance phase of OIT in real life.
methodsProspective study of all children and adolescents, who underwent CM-OIT and were subsequently followed at our allergy center on maintenance dose (200 mL daily) for at least 36 months after reaching the maintenance phase (from 2009 to 2016).
resultsForty-two patients were enrolled: 60% male, 36% with history of anaphylaxis and 57% with asthma. The median time of follow-up was 69 months (range, 39-105 months) and the median age at the last clinical evaluation was 13 years (range, 6-23 years). Regarding adherence to the protocol: 92% are on free diet (at least 200 mL of CM daily; 7-g protein); 14% had transient interruptions and 7% definitely withdrawn with loss of tolerance. During maintenance, 45% developed mild to severe allergic reactions, and 7% had more than 3 episodes. A positive correlation between the occurrence of allergic reactions and history of anaphylaxis (
conclusionThis real-life study supports long-term efficacy and safety of CM-OIT. Despite daily intake, 41% had symptoms at some moment during the complete follow-up period; a total of 33 symptomatic days in patients with mean follow-up time of 67.5 months. Clinical tolerance depends on daily intake. The protective effect reached can be lost after CM withdrawal. History of anaphylaxis was a risk factor for the occurrence of allergic reactions during the maintenance phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.